Trial
NCT00547066
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Purpura, Thrombocytopenic, Idiopathic
Intervention
veltuzumab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-16